FDA grants Priority Review of NDA for Astex's oral C-DEC
Category: #health  By Saipriya Iyer  Date: 2020-02-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

FDA grants Priority Review of NDA for Astex's oral C-DEC

Astex Pharmaceuticals, Inc., a subsidiary of Otsuka Pharmaceutical Co. Ltd., announced that it has received Priority Review for its NDA for oral C-DEC (cedazuridine and decitabine) by the U.S. Food and Drug Administration (FDA). Oral C-DEC is a treatment modality under development for adults with previously untreated high-and intermediate-risk MDS, such as chronic myelomonocytic leukemia (CMML). The proposal for NDA is supported by the data received from the ASCERTAIN phase 3 trial, which assessed the 5-day decitabine exposure equivalence of IV decitabine and oral C-DEC.

Dr. Mohammad Azab, MD, Chief Medical Officer and President, Astex Pharmaceuticals, Inc., reportedly stated that the company is gratified to receive acceptance of its NDA for Priority Review from the FDA and elated by the contribution of all the investigators, patients, other healthcare providers, and partner research & manufacturing organizations to the clinical development program of oral C-DEC. The oral C-DEC may offer a novel treatment alternative for patients suffering from CMML and MDS and release the burden of taking 5-day IV infusions every month during therapy, he further added.

The FDA accepts Priority Review applications of drugs, which, after approval, can deliver significant improvements in the effectiveness and safety of the medication, diagnosis or prevention of severe conditions. The Priority Review designation indicates the goal of the FDA to act on an NDA application in six months as compared to the ten months under standard review.

For the record, oral C-DEC is an investigational compound, which has not yet received any approval in any country.

In another news, the parent company of Astex, Otsuka Pharmaceutical Co., Ltd., and Taiho Pharmaceutical Co., Ltd. announced that commercialization of oral C-DEC in Canada and the U.S. will be conducted by Taiho Pharma Canada, Inc. and Taiho Oncology, Inc. respectively. The commercialization will be subject to regulatory approvals.

Source link:

https://astx.com/astex-pharmaceuticals-announces-u-s-food-and-drug-administration-fda-acceptance-for-review-of-an-nda-for-the-combination-oral-hypomethylating-agent-cedazuridine-and-decitabine-astx727-or-oral-c-de/



About Author

Saipriya Iyer

Email: [email protected]tsizeforecasters.com   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Alibaba to acquire 10% stake in Yunda from controlling shareholders
Alibaba to acquire 10% stake in Yunda from controlling shareholders
By Saipriya Iyer

Alibaba Group Holding Limited, a Chinese multinational technology company, is reportedly planning to purchase nearly 10% stakes in Yunda Holding Co Ltd. This acquisition marks the e-Commerce company’s 5th investm...

Amazon warehouse workers plan walkout in NYC due to COVID-19 fear
Amazon warehouse workers plan walkout in NYC due to COVID-19 fear
By Saipriya Iyer

A group of Amazon workers at its New York City facility reportedly held a walk out and went on strike over the lack of safety protocols by the e-Commerce giant, amid COVID-19 pandemic concerns. These workers further de...

Regeneron-Sanofi announce 1st patient for clinical study outside U.S.
Regeneron-Sanofi announce 1st patient for clinical study outside U.S.
By Saipriya Iyer

Regeneron Pharmaceuticals, Inc. & Sanofi have recently announced the 1st patient to be treated in the COVID-19 clinical program, outside of the United States. The study, which is anticipated to enroll nearly 300 pa...